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Simple Summary: This paper is a review of the literature on the clinical role of oncomarkers in
idiopathic pulmonary fibrosis (IPF) progression, and a description of the routine oncomarker trend in
IPF patients over the longest follow-up yet reported. This is the first meta-analysis to review the results
of studies evaluating the predictive prognostic value of circulating oncomarkers (CEA, Ca15.3, Ca19.9,
Ca125, and KL-6) for IPF. The study focused on the discovery of multiple biomarker signatures, such
as combinations of oncomarkers, that are widely and routinely available in biochemistry laboratories.
The combination of clinical parameters and biological markers could help achieve more accurate
results regarding prognosis and response to treatment in IPF. Our results could pave the way for a
more “personalized” medical approach to patients affected by IPF.
Abstract: Background: Idiopathic pulmonary fibrosis (IPF) is a severe progressive interstitial lung
disease. At 5-year follow-up, 15% of IPF patients develop lung cancer, which significantly reduces
the survival rate. Here we review the literature on the clinical role of oncomarkers in IPF progression,
and describe the trend of routine oncomarkers in IPF patients over the longest follow-up yet reported.
Materials and methods: A systematic search of the literature in PubMed was performed to find
relevant studies published up to 24 September 2020. The most common oncomarkers were chosen to
select papers related to pulmonary fibrosis. Then, 24 IPF patients and 25 non-IPF patients, followed at
Careggi ILD Referral Centre and Siena Regional Referral Centre for ILD, were enrolled consecutively.
Results: A few studies reported an association between serum oncomarkers and severity of IPF.
NSE, CEA, Ca19.9, and Ca125 were higher in the IPF, than in the non-IPF, group at every follow-up
(p < 0.05). Ca15.3 concentrations were higher in the IPF, than the non-IPF, group at t3 (p = 0.0080)
and t4 (p = 0.0168). To improve the specificity and sensitivity of Ca15.3, a panel of biomarkers was
analyzed, with the IPF group as dependent variable, and chitotriosidase, Cyfra 21.1, Ca15.3, Ca125,
and Ca19.9 as independent variables. Conclusions: This study focused on the discovery of multiple
biomarker signatures, such as combinations of oncomarkers, that are widely and routinely available
in biochemistry laboratories. The combination of clinical parameters and biological markers could
help achieve more accurate results regarding prognosis and response to treatment in IPF. Our results
could pave the way for a more “personalized” medical approach to patients affected by IPF.
Keywords: idiopathic pulmonary fibrosis; oncomarker; lung cancer
1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial
pneumonia of unknown cause, occurring primarily in older adults, and limited to the
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lungs [1]. Recent meta-analyses have shown close associations between the development
of IPF and lung cancer [2–4]. Both usually affect the periphery of lower lung lobes, shar-
ing common risk factors (e.g., smoking, environmental or occupational exposure, viral
infections, and chronic tissue injury) and pathogenic mechanisms, such as epigenetic and
genetic alterations, abnormal expression of microRNAs, cell and molecular aberrations
(e.g., altered responses to regulatory signals, delayed apoptosis, and reduced cell-to-cell
communication), and activation of specific signal transduction pathways [5]. In the PRO-
FILE (prospective observation of fibrosis in the lung clinical endpoints) study, some of these
oncomarkers, especially Ca19.9 and Ca125, were associated with increased mortality [6].
Very recently Balestro et al. corroborated the prognostic value of Ca19.9 in end-stage
IPF [7]. Although several authors have reported high concentrations of common onco-
markers, including carcinoembryonic antigen (CEA) [8], cancer antigen 19.9 (Ca19.9) [9],
15.3 (Ca15.3) [10], 125 (Ca125) [8], and Krebs von den Lungen-6 (KL-6) [11–14], in IPF,
little data is available on the prognostic role of all these markers, taken together, and their
interactions, in IPF progression [9,15]. Here we review the literature on the clinical role
of oncomarkers in IPF progression and describe the trend of routine oncomarkers in IPF
patients over the longest follow-up yet reported.
2. Results
2.1. Systematic Review and Metanalysis
2.1.1. Search of the Literature
Figure 1 shows the flow diagram of the present systematic review. Mean concen-
trations and standard deviations (SD) of circulating oncomarkers were extracted from
10 studies for patients with and without IPF (IPF patients: n = 1757, non-IPF: n = 1508).
Baseline circulating levels of serum oncomarkers of patients with and without IPF were
obtained from all studies [9,10,15–22] to explore the predictive value for IPF progression
(including development of lung cancer). Assessment of disease progression was performed
according to the evaluation of pulmonary functional parameters (forced vital capacity (FVC)
and/or diffusing capacity for carbon monoxide (DLCO)) and/or computed tomography
(CT) features.
2.1.2. Meta-Analysis Results
Higher concentrations of carcinoembryonic antigen (CEA) and Ca-125 were recorded
in IPF patients with lung cancer, than in non-IPF patients (I2 = 92.3%, p < 0.001, mean CEA
concentrations (IPF vs. non-IPF): 5.35 vs. 4.89 ng/mL; I2 = 91.9%, p < 0.001, mean Ca125
concentrations (IPF vs. non-IPF): 34.68 vs. 32.09 U/mL) (Figure 2a,b).
Serum concentrations of Ca15.3 (I2 = 88.8%, p = 0.001, mean (IPF vs. non-IPF):
91.02 vs. 16.3 U/mL), Ca19-9 (I2 = 97.3%, p < 0.001, mean (IPF vs. non-IPF): 54.71 vs.
15.29 U/mL) and KL-6 (I2 = 91.9%, p < 0.001, mean (IPF vs. non-IPF): 1164 vs. 317 U/mL)
were associated with disease progression in IPF patients (Figure 3a–c). In particular, higher




The main characteristics of our population are reported in Table 1. As expected, IPF
patients were predominantly male (81.4%), over 65 years of age and most had a history
of cigarette smoking (75%). Velcro crackles were audible by chest auscultation in all
IPF patients, and significantly more often than in non-IPF patients (Table 1). Dyspnea
expressed as modified Medical Research Council (mMRC) score was statistically different
in the IPF and non-IPF groups at t3 (p = 0.0070). In the IPF group, mMRC score at t0
differed from those at subsequent follow-up times (p = 0.0001). At 18-month follow-up (t3),
three IPF patients had died, while no patient had died in the non-IPF group. Stratifying
the study population according to therapy with pirfenidone or nintedanib, we did not
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observe any statistically significant difference of oncomarker concentrations or functional
disease progression.




Figure 1. Flow diagram of chosen studies for the present metanalysis. 
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Table 1. The mai characteristics of our population divided in idiopathic pulmonary fibrosis (IPF)
and non-IPF groups. 1 and 2: older and prevalence of males in the IPF group (p < 0.05), respectively.
3. Velcro sound was prevalent in the IPF group (p < 0.05). Abbreviations: modified Medical Res arch
Council (mMRC).
IPF (n = 24) Non-IPF (n = 25)
Age (yr) 73.80 ± 7.79 1 62.43 ± 13.63
Sex (M/F) 22/2 2 14/11
Smoking history (>5 p/yr) 18/24 12/25
Familiarity for ILD (yes/no) 2/24 1/25
Cough (VAS > 3/10 cm) 22/24 17/25
Dyspnea (mMRC > 1/4) 16/24 14/25
Velcro sound (yes/no) 23/24 3 8/25
Clubbing (yes/no) 3/24 1/25
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concentrations of selected studies, (c) metanalysis results from KL-6 concentrations of selected studies.
Statistical analysis was performed comparing each sampling time for each group (IPF:
t0 vs. t1, t0, vs. t2, etc.); moreover, a comparison analysis was performed between the two
subgroups (IPF t0 vs. non-IPF t0, IPF t1 vs. non-IPF t1, etc.).
Serum concentrations (Figure 4a,b) of chitotriosidase and oncomarkers Cyfra 21.1,
Ca19.9, and Ca125 were in the normal range at t0 in the IPF and non-IPF groups. As
expected, serum chitotriosidase was higher in the non-IPF group in relation to the presence
of sarcoidosis patients (p < 0.05) [23–27]. This trend remained unchanged even at 18-month
follow-up.
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Figure 4. (a) Serial concentrations of oncomarkers in the IPF group. (b) Serial oncomarker concentrations in the non-IPF group.
The non-IPF group showed l wer CEA co centrations at t0 than at t3 (p = 0.0294) a d
t4 (p = 0.0019) and the difference was statistically significant between t1 and t4 (p = 0.0327).
Comparing oncomarker concentrations in the two groups, neuron specific enolase (NSE),
CEA, Ca19.9 and Ca125 were higher in IPF patients than in the non-IPF group at every
follow-up (p < 0.05). Ca15.3 concentrations were higher in the IPF than the non-IPF group
at t3 (p = 0.0080) and t4 (p = 0.0168).
In IPF group patients, serum conce trations of Ca15.3 showed a statistically significant
increase in the intervals t0–t3 (p = 0.0369), t0–t4 (p = 0.0142), t1–t3 (p = 0.0350), and t2–t4
(p = 0.043).
CEA had the greatest sensitivity and specificity for distinguishing IPF and non-IPF
p tients at all follow-up times (Table 2).
Table 2. Receiver operating characteristic (ROC) curve analysis between IPF and non-IPF patients according to oncomarker
concentrations at each sampling time. Abbreviations: t0, baseline; t1, 6 months; t2, 12 months; t3, 18 months; t4, 24 months.
IPF vs. Non-IPF AUC p Value Cut-Off Value Sensitivity Specificity
NSE, t0 76 0.0016 7.75 72 70.8
NSE, t1 77.1 0.0012 4.96 68 79.2
NSE, t2 76.7 0.0014 7.95 72 66.7
NSE, t3 77.4 0.0010 4.65 72 75
NSE, t4 71.6 0.0096 5 72 70.8
CEA, t0 94 <0.0001 2.55 96 87.5
CEA, t1 99.7 <0.0001 2.85 96 95.8
CEA, t2 95.6 <0.0001 2.85 92 95.5
CEA, t3 98.8 <0.0001 2.85 88 95.8
CEA, t4 98.1 <0.0001 3.3 88 95.8
Ca19.9, t0 78.4 0.0006 12.6 76 79.2
Ca19.9, t1 77 0.0012 11.9 72 79.2
Ca19.9, t2 78.2 0.0007 11.2 68 79.2
Ca19.9, t3 79.6 0.0004 9.7 68 79.2
Ca19.9, t4 81.6 0.0002 8.3 68 83.3
Ca15-3, t3 69.9 0.0168 31.6 72 54.2
Ca15-3, t4 67.7 0.0340 29.3 60 62.5
Ca125, t0 71.4 0.0114 8.8 68 66.7
Ca125, t1 72.1 0.0008 8.7 68 66.7
Ca125, t2 74.2 0.0036 9.3 68 66.7
Ca125, t3 73.8 0.0042 7.2 72 66.7
Ca125, t4 71.5 0.0099 9.5 76 62.5
In order to improve the specificity and sensitivity of Ca15.3, a panel of biomarkers
was analyzed. With the IPF group as dependent variable, and chitotriosidase, Cyfra 21.1,
Ca15.3, Ca125, and Ca19.9 concentrations at t0 as independent variables, the area under the
receiver operating curve (AUROC) obtained by logistic regression was 88% (95% CI 78–97,
NPP 82.6%, and PPP 76.9%, p < 0.0001) (Figure 5). With the same biomarker concentrations
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at t1, t2, t3, and t4 as independent variables, we repeated the logistic regression. At t1, we
obtained an AUROC of 85% (95% CI 74–95, NPP 70.8%, and PPP 68%, p < 0.0001) (Figure 5),
at t2, 86% (95% CI 76–96, NPP 78.3%, and PPP 73.1%, p < 0.0001) (Figure 5), at t3, 86% (95%
CI 76–96, NPP 80%, and PPP 79.2%, p < 0.0001) (Figure 5) and at t4, 86% (95% CI 75–96, NPP
78.3%, and PPP 73.1%, p < 0.0001) (Figure 5). With respect to a single biomarker, the panel
increased sensitivity and specificity in discriminating the two groups at all follow-up times.




Figure 5. The analysis of logistic regression reporting t0, t1, t2, t3, and t4 oncomarkers panel in the IPF
vs. the non-IPF group.
Regarding lung function (Figure 6), FVC%, forced expiratory volume in 1 s (FEV1%),
total lung capacity (TLC)%, and DLCO% decreased significantly in the interval t0–t4 in
IPF patients compared to non IPF patients. TLC and DLCO percentages were lower in the
IPF than in the non IPF group at all follow-ups. In IPF patients, all functional parameters
were significantly different (p < 0.01) at t3 with respect to t2 and t0 (p < 0.01). No significant
differences (p > 0.01) in lung function parameters were observed in non-IPF patients in the
serial follow-up.
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Figure 6. (a) IPF serial changes of pulmonary function test (PFT) parameters (b) non-IPF serial changes PFT parameters.
The trend of functional parameters in the IPF population showed a progressive statis-
tically significant decline at t3 and t4 (p < 0.05). Due to the limited statistical sample, no
correlations between serological biomarkers and survival data could be detected. Correla-
tion analysis between serum biomarkers and lung function parameters in the two groups
are shown in Table 3. Interestingly, there was a significant negative correlation between
serum concentrations of CEA and FEV1, FVC and DLCO percentages at t3 and t4.
Table 3. Correlation analysis between serum biomarkers and pulmonary function test (PFT) parameters in the two
subgroups. Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; DLCO, diffusing lung
for carbon monoxide; CEA, carcinoembryonic antigen; TLC, total ling capacity.
IPF Rho Coefficient p Value Non-IPF Rho Coefficient p Value
t0 t0
CEA TLC −0.48 0.018 Chito FVC 0.476 0.016
Cyfra21.1 DLCO −0.43 0.036 FEV1 0.425 0.034
t1 TLC 0.422 0.035
Chito DLCO 0.511 0.011 t1
Cyfra21.1 DLCO −0.44 0.031 Chito FVC 0.605 0.001
t2 FEV1 0.662 0.0003
CEA FVC − .501 0.013 TLC 0. 15 08
CEA FEV1 −0.524 0.009 DLCO 0.490 0.013
Cyfra21.1 FEV1 −0.430 0.036 t2
t3 Chito FVC 0.636 0.0006
Chito FVC 0.416 0.043 FEV1 0.710 0.0001
Chito FEV1 0.429 0.037 TLC 0.522 0.0075
CEA FVC −0.682 0.0002 DLCO 0.477 0.0252
FEV1 .81 0.00 001 NSE TLC −0.480 15
CEA DLCO −0.647 0.001 CEA FEV1 −0.529 0.007
Ca19.9 FVC −0.458 0.024 TLC −0.418 0.038
Ca15-3 FEV1 . 9 0.032 DLCO −0.423 0.035
t4 Ca19.9 TLC −0.411 0.041
Chito FEV1 0.54 0.006 t3
CEA FVC −0.803 0.000002 Chito FVC 0.635 0.0006
CEA FEV1 −0.852 0.0000 01 FEV1 0.783 0.0 004
CEA TLC −0.464 0.022 TLC 0.579 0.002
CEA DLCO −0.520 0.009 DLCO 0.509 0.0093
Cyfra21.1 FVC .427 0.037 TLC −0.510 09
FEV1 −0.505 0.012 DLCO −0.410 0.0417
CEA TLC −0.461 0.02
Ca19.9 TLC −0.461 0.0387
Ca125 TLC −0.408 0.0431
t4




NSE TLC −0.431 0.032
Ca19.9 TLC −0.419 0.037
Ca125 TLC −0.405 0.045
Abbreviations: t0, baseline; t1, 6 months; t2, 12 months; t3, 18 months; t4, 24 months.
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3. Discussion
This is the first meta-analysis to review the results of studies evaluating the predictive
prognostic value of circulating oncomarkers (CEA, Ca15.3, Ca19.9, Ca125, and KL-6) for
IPF. Although oncomarker concentrations were higher in IPF than non-IPF patients, no
data were available on IPF progression, including mortality. A few studies have found
higher levels of circulating oncomarkers in IPF than in non-IPF patients [8–10,15,16,18,22].
The present study showed that higher circulating levels of CEA, Ca15.3, Ca19.9, and Ca125
in IPF patients than in non-IPF patients may be due to the common molecular pathways
shared by IPF and lung cancer. Moreover, increased KL-6 production may be due to
regenerating type II alveolar epithelial cells, and/or increased permeability caused by
damage to the air–blood barrier in interstitial lung disease (ILD) [14].
A few studies have reported an association between serum oncomarkers and severity
of IPF, and only two papers have evaluated the association with survival of these patients.
These papers reported that elevated CEA and Ca125 concentrations were associated with in-
creased risk of lung cancer in IPF patients with similar cut-off values [8,16]. Kodama T et al.
suggested that clinicians pay attention to evidence that elevated serum levels of CA19.9
may be related to poor prognosis in IPF patients [9]. Balestro et al. recently reported CA
19-9 as a disease severity marker in patients with end-stage ILD, demonstrating an inverse
correlation of this oncomarker with functional decline, particularly among patients with
rapidly progressive IPF [7]. Ca15.3 has been studied in relation to the pathogenesis of IPF,
and it has been associated with survival and disease severity, due to an inverse correlation
between DLCO and high-resolution computed tomography (HRCT) findings [15].
One study showed a significant negative correlation of serum KL-6 levels with FEV1
and FVC percentage [21]. The present study also found that circulating KL-6 levels were
highly valuable in the prognosis of IPF [20], indicating a significant association between
the baseline levels of circulating KL-6 and mortality in IPF.
In the present study, we evaluated serial changes in chitotriosidase and circulating
oncomarkers in a cohort of ILD patients divided into IPF and non-IPF groups. Increased
chitotriosidase values have been repeatedly reported in sarcoidosis patients, and may
predict clinical course and potential relapse of the disease [23–28]. As expected, serum
chitotriosidase in our non-IPF group was high in relation to the presence of sarcoidosis
patients. Moreover, significant direct correlations between chitotriosidase and functional
parameters were observed in the non-IPF group at baseline, and overtime, confirming the
role of this protein as a potential prognostic marker.
The clinical course of IPF is variable, ranging from slow progression over many years,
to acute exacerbation and rapid loss of lung function. This, associated with a lack of
biomarkers to predict disease progression and response to treatment, makes the clinical
management of IPF very challenging [29–35]. Thus, interest has been focused on the
discovery of multiple biomarker signatures that could be used more effectively in the
diagnosis and prognosis of IPF. In 2016, White and co-workers developed a panel of
35 extracellular matrix, extracellular matrix-related, and lung-specific analytes, measured
in the plasma of IPF patients, to create a diagnostic score [36]. Other studies have shown
increased prognostic accuracy when serum biomarkers were used in combination [37,38].
The combining of clinical parameters and biological markers has been studied in order to
achieve more accurate results regarding the prognosis of IPF [12,36]. In this context, the
present study identified and validated new biomarkers of IPF for their prognostic potential.
Serial concentrations of NSE, CEA, Ca19.9, and Ca125 were higher in IPF than in non-IPF
patients at each follow-up. In particular, Ca15.3 concentrations were higher in the IPF than
in the non-IPF group at t3 and t4, and showed an increasing trend.
Significant correlations between oncomarkers and several functional parameters were
found. In particular, CEA showed an indirect correlation with FEV1%, FVC%, and DLCO%
decline at 18- and 24-month follow-up in IPF patients with respect to non-IPF patients. Our
findings were in line with those of a prospective study by Fahim et al., who demonstrated
elevated serum concentrations of CEA in IPF patients, and a significant negative correlation
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of the latter with lung function parameters [39]. Moreover, a mechanism of elevation of
this tumor antigen is suggested by immunohistochemical evidence of CEA staining of
metaplastic alveolar epithelium lining honeycomb cysts and respiratory bronchioles [39].
Although the exact mechanism is unknown, the atypical epithelial proliferation and squa-
mous metaplasia seen in lung biopsies of patients with idiopathic interstitial fibrosis may
be one of the mechanisms responsible for increased CEA in IPF. In addition to elevation
of CEA in pulmonary fibrosis of unknown etiology, there is evidence of significantly ele-
vated levels of cancer antigen Ca15.3 in IPF and advanced sarcoidosis [10,40]. Fujita and
colleagues showed intense staining of Ca15.3 in fibroblasts of fibroblastic foci and lung
fibroblast cultures from IPF patients [41].
Our results showed that CEA had the greatest sensitivity and specificity in distinguish-
ing IPF from non-IPF at all follow-up times. Ca15.3 had a low sensitivity, but was the only
marker to show a rising trend in IPF. However, a panel consisting of chitotriosidase, Cyfra
21.1, Ca15.3, Ca125, and Ca19.9 showed better sensitivity and specificity at all follow-up
times than any single biomarker in distinguishing IPF from non-IPF patients. Histological
assessment of Ca19.9 and Ca125 suggested that these proteins were markers of epithelial
damage [40]. In the PROFILE study, these biomarkers were both associated with high
mortality [6]. If these findings are corroborated in future studies, Ca125 and Ca19.9 could
become point-of-care prognostic markers.
Our data confirms the previous findings of higher serum levels of oncomarkers (Ca125,
Ca15.3, Ca19.9, and CEA) in IPF than in non-IPF patients. Ca15.3 was correlated with poor
prognosis. Interestingly, all except CEA decreased significantly after lung transplant [9].
It would be worthwhile validating these interesting results in multicentric prospective
studies with a larger sample of patients. It would also be interesting to measure oncomarker
concentrations in other biological materials.
The limitations of the present study were the relatively small number of studies found
for the meta-analysis, which did not enable us to explore the sources of heterogeneities.
4. Materials and Methods
4.1. Systematic Review and Metanalysis
4.1.1. Search of the Literature
A systematic search of the literature in PubMed was performed to find relevant stud-
ies published before 24 September 2020, and limited to the following publication types
(clinical study, journal article, multicenter study, observational study), species (human),
and languages (English). The most common oncomarkers (Ca15.3, Ca19.9, Ca125, alpha-
fetoprotein, prostate-specific antigen, calcitonin, chromogranin A, neuron-specific enolase,
Cyfra 21-1, human chorionic gonadotropin, S100, thyroglobulin, and KL-6) were chosen
in order to select papers related to pulmonary fibrosis. The following medical subject
headings were searched in (Title/Abstract): (“Ca-15-3” or “Ca15.3” “pulmonary fibrosis”),
(“Ca19.9” “pulmonary fibrosis”), (“Ca125” “pulmonary fibrosis”), (“CEA” “pulmonary
fibrosis”), (“alpha-fetoprotein” “pulmonary fibrosis”), (“prostate specific antigen” “pul-
monary fibrosis”), (“calcitonin” “pulmonary fibrosis”), (“chromogranin A” “pulmonary
fibrosis”), (“neuron specific enolase” or “NSE” “pulmonary fibrosis”), (“Cyfra 21-1” “pul-
monary fibrosis”), (“human chorionic gonadotropin” “pulmonary fibrosis”), (“S100” or
“calgranulin” “pulmonary fibrosis”), (“thyroglobulin” “pulmonary fibrosis”), (“Krebs von
den Lungen-6” or “KL-6” or “MUC1” “pulmonary fibrosis”).
4.1.2. Study Selection
Studies were included in the meta-analysis when they met the following criteria:
studies focused on patients diagnosed with IPF according to the results of chest radio-
graphy, conventional thoracic computed tomography, HRCT, and pulmonary function
tests (either FVC% or DLCO% < 80%); oncomarkers identified in serum; homogeneous
units of measurement and methods of detection of oncomarkers; studies that provided
sufficient data to complete cross-tabulations (2 × 2 tables) for evaluating the diagnostic
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accuracy of serum oncomarkers in IPF versus non-IPF patients. When the same population
was published in different reports, the most recent or complete report was included. Case
reports, case series, reviews, letters and conference abstracts were excluded due to limited
assessment or analysis of data. Studies with insufficient data (or that only reported the
cut-off value) for completing cross-tabulations were excluded as well.
4.1.3. Data Collection and Meta-Analysis
Data was extracted from eligible studies and summarized independently by two
researchers (MD and LB). Any disagreement was resolved by consensus. The following
information was collected from each study: first author’s name, year of publication, disease
subtypes, affiliation of study, ethnicity of population, assay method, cut-off value, sample
size, number of case groups, number of control groups. From cross-sectional studies we
extracted mean concentrations and standard deviations (SD) of circulating oncomarkers in
patients with and without IPF.
These data were processed with Covidence, Jamovi, and GraphPad Prism 9 software.
For cross-sectional studies, the standard mean difference (SMD) and 95% CI were computed
as the effect size of following comparisons: IPF vs. non-IPF. Heterogeneity between studies
and the amount of variation derived from heterogeneity were evaluated by Q test and I2,
respectively. When heterogeneity was high (p value for Q test ≤ 0.05, I2 ≥ 50%), random
effects models were used as a pooling method.
4.2. Original Contribution
4.2.1. Study Population
Seventy-nine ILD patients followed at Careggi Interstitial Lung Diseases Referral Cen-
tre and Siena Regional Referral Centre for ILD were enrolled consecutively. Twenty-four
diagnosed with idiopathic pulmonary fibrosis (IPF) and 25 non-IPF patients diagnosed with
nonspecific interstitial pneumonia (NSIP) (n = 9), sarcoidosis (n = 8), pleuroparenchymal fi-
broelastosis (PPFE) (n = 2), respiratory bronchiolitis associated with ILD (RB-ILD), subacute
hypersensitivity pneumonitis (HP) (n = 4), and cryptogenic organizing pneumonia (COP)
(n = 2) were selected for consecutive serial evaluation of oncomarkers. We excluded IPF
patients with a follow-up inferior to 24 months, those patients with concomitant infection,
malignancy and acute exacerbation compliance, or those patients with non-definite usual
interstitial pneumonia (UIP) pattern at CT scan. All the diagnoses were confirmed by
multidisciplinary discussion, according to international guidelines (ATS/ERS).
Of this selected population, 15 IPF patients (62.5%) were treated with pirfenidone
and nine (37.5%) with nintedanib. Non-IPF patients were treated with corticosteroids
(n = 16, 64%) and immunosuppressant therapy (azathioprine, mycophenolate ecc descrivere)
(n = 9, 36%). All patients were naïve for therapies at the time of diagnosis (t0), and started
nintedanib or pirfenidone treatments according to Italian national drug inclusion criteria.
Medical history, physical examination, age, sex, ethnicity, BMI, vital signs, onset
of symptoms, hospitalizations, concomitant diseases, smoking history, occupational his-
tory, current and previous therapy, blood gas analysis, and 6-minute walking test were
recorded in a database. All patients gave written informed consent to participation in the
study, which was approved by the local ethics committee CEAVSE (code number 180712;
Markerlung 17431).
4.2.2. Methods
Lung function tests were performed according to ATS/ERS recommendations using
a plethysmograph with corrections for temperature and barometric pressure and the
parameters were expressed as % of predicted value: forced expiratory volume in 1 s
(FEV1%), (FVC%), (DLCO%) by the single-breath method, and total lung capacity (TLC%).
A six-minute walking test was performed according to international recommendations.
These measurements were obtained from all patients able to perform lung function tests.
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Serum samples for assay of the following proteins/oncomarkers were drawn at
baseline t0 and every 6 months of follow-up (6 months (t1), 12 months (t2), 18 months
(t3), and 24 months (t4)): chitotriosidase (chitinase-1), carcinoembryonic antigen (CEA),
cancer antigen 15-5 (Ca15-3), neuron-specific enolase (NSE), cancer antigen 19-9 (Ca19-9),
cytokeratin fragment 21-1 (Cyfra 21.1), and cancer antigen 125 (Ca-125). Oncomarkers and
chitotriosidase were assayed as previously reported [7,8,10,23,39,42,43].
4.2.3. Statistical Analysis
Data was expressed as mean ± standard deviation or median and interquartile range.
Non-parametrical tests were adopted for data analysis: Kruskal–Wallis and Dunn’s mul-
tiple tests to compare the two groups (IPF and non-IPF) and to compare the sampling
times each other (t0, t1, t2, t3, t4). The Chi-squared test was used for categorical variables,
as appropriate. The oncomarkers analyzed in this study were commonly used in clinical
practice and the cut-off values were standardized: CEA > 2.5 ng/mL (normal value 0 to
2.5–3 ng/mL), Ca15-3 > 35 UI/mL (n.v. 0 e 32.4 U/mL), NSE > 15 (n.v. 0 to 15 ng/mL),
Ca19-9 > 40 U/mL (n.v. 0–40 U/mL), Cyfra 21.1 > 3.5 mcg/mL (n.v. 0 to 3.5 mcg/mL), and
Ca125 > 35 UI/mL (n.v. 0–35 UI/mL).
Serum biomarker concentrations were also compared between groups, assessing
areas under (AUC) the receiver operating characteristic curves (ROC). Logistic regression
analysis, using the IPF group as dependent variable against non-IPF patients, to assess the
potential of serum markers in discriminating the two groups at each sampling time, was
adopted. Sensitivity, specificity, and positive and negative predicted values (PPV and NPV,
respectively) were calculated for cut-off of the different variables. The Spearman test was
used to look for correlations between variables. A p value less than 0.05 was considered
statistically significant. All the statistical analysis and the related figures were carried out
using GraphPad Prism 8.4 software.
5. Conclusions
In conclusion, the study focused on the discovery of multiple biomarker signatures,
such as combinations of oncomarkers, that are widely and routinely available in biochem-
istry laboratories. The combination of clinical parameters and biological markers could
help achieve more accurate results regarding prognosis and response to treatment in IPF.
Our results could pave the way for a more “personalized” medical approach to patients
affected by IPF.
Biomarkers are relevant in medicine, particularly in the realm of “personalized
medicine”. Disease severity biomarkers are helpful tools, and they are valuable for pre-
dicting prognosis. It is known that every patient can have a different response to a specific
therapeutic approach according to several immunological features. Our results could
pave the way for a more “personalized” medical approach to patients affected by IPF
monitoring oncobiomarkers.
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